Nancy Freda Smith, a director at Tempest Therapeutics, Inc., has reported a stock option transaction involving 25,000 shares. This event is significant as it illustrates the ongoing commitment of company executives to their roles and the potential for future growth within the organization.
Background
Tempest Therapeutics, Inc. operates in the pharmaceutical preparations sector, focusing on innovative treatments and therapies. The company is incorporated in Delaware and has its fiscal year ending on December 31. Recent filings include a Form 4 and a Form 3, both filed on October 2, 2026, indicating active reporting by its directors and executives.
What the Filing Says
According to the filing, Smith acquired 25,000 stock options at an exercise price of $1.00 per share on September 22, 2026. The filing notes, "The shares subject to each such stock option will vest over a three-year period, with one-third of the award vesting on the first anniversary of the grant date and the remainder of the award vesting in equal monthly installments thereafter, subject to the Reporting Person's continued service." This structured vesting schedule emphasizes the importance of ongoing commitment from Smith to the company.
Impact
This transaction may affect shareholders and potential investors in Tempest Therapeutics, as it reflects the confidence of leadership in the company's future. The pharmaceutical preparations sector is known for its volatility, and executive transactions can influence market perceptions and investor sentiment.
What's Next
The filing does not say what happens next.
Read Next
Saba Capital Management Disposes of Shares in PIMCO Fund
Wang Yanjun Reports Multiple Stock Sales at Sea Ltd
Summit Therapeutics' Co-CEO Exercises Stock Options for 500,000 Shares
Kim Vyacheslav Sells Shares of Kaspi.kz in Recent Transactions
Summit Therapeutics Co-CEO Exercises Stock Options for 500K Shares
King David Arnold buys 6,000 shares of Kratos Defense






